Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Pertuzumab
Related studies linked through entity extraction aliases.
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
- Status
- RECRUITING
- Phase
- PHASE2
A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
- Status
- RECRUITING
- Phase
- PHASE3
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
The Sagittarius Trial
- Status
- RECRUITING
- Phase
- PHASE3
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
- Status
- RECRUITING
- Phase
- PHASE3
Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
- Status
- RECRUITING
- Phase
- PHASE1
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
- Status
- RECRUITING
- Phase
- PHASE2
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2